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Abstract
Background: Monopolar radiofrequency ablation (RFA) is a well accepted modality for local control of
hepatic tumours, but its effectiveness is challenged by prolonged ablation time, an inconsistent ablation
zone and susceptibility to energy loss from convective heat loss from adjacent high-velocity blood flows
(‘heat sinks’). Bipolar RFA employs a dual parallel electrode array; the energy wave travels unidirectionally
between and not around electrodes. This ‘line-of-sight’ delivery streams energy between two fixed points
and concentrates energy delivery to the area between the probes. Bipolar RFA is postulated to yield
reduced ablation time and to reduce or eliminate convective heat loss from adjacent high-velocity blood
flows. The current study evaluated the feasibility, time and safety of this novel FDA-approved bipolar RFA
technology using a laparoscopic approach in human liver tumours.
Methods: Using the prospectively maintained surgical oncology hepatic-pancreatic-biliary database, 17
consecutive patients (26 liver tumours) who underwent laparoscopic bipolar ablations were reviewed.
Electrodes were placed using guidance by intraoperative ultrasound and trajectory planning needles.
Ablation time was recorded and postoperative computed tomography scans were obtained.
Results: A total of 18 lesions (in 12 patients) represented metastatic colorectal cancer. Three lesions (in
two patients) were hepatocellular carcinoma. Four lesions (in two patients) represented locally advanced
symptomatic gallbladder cancer invading the liver bed or symptomatic intrahepatic liver metastases from
gallbladder cancer. One lesion was benign hepatic adenoma. Mean tumour size was 3.07  1.42 cm.
Mean ablation time was 358  120 sec. No major complications were observed in the 30-day or
>30-day periods post-RFA.
Conclusions: Laparoscopic bipolar RFA is a quick, safe technique which adds a new tool to our
armamentarium for treating hepatic tumours. Establishing its longterm oncological outcome will require
longer follow-up and the exact role of this technique in the current multimodality management remains to
be defined.
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Introduction
A large proportion of primary or metastatic hepatic tumours are
unresectable for various reasons, including those of anatomic
location or patient co-morbidities; this has led to the emergence
and development of various non-resectional liver-directed thera-
pies. These therapies can be broadly divided into two groups
comprising regional transarterial therapies, and local (chemical
and thermal) ablative therapies.1 Thermal therapies include cold
method (cryoablation) and hot methods (monopolar radiofre-
quency ablation [RFA], bipolar RFA and microwave ablation
[MWA]).
Monopolar RFA is well accepted as a local tumour control
modality for unresectable primary or metastatic hepatic
DOI:10.1111/j.1477-2574.2008.00024.x HPB
HPB 2009, 11, 135–139 © 2009 International Hepato-Pancreato-Biliary Association
tumours.2 Monopolar energy streams from the source outwardly
in all directions and is subject to the inverse square law which
causes a geometric reduction in energy density, so that a non-
array single-needle monopolar electrode results in only a 1.0–
1.5-cm sphere of tissue ablation. Furthermore, monopolar
ablation is subject to premature electrode tip charring, which
often results in rapid tissue heating, increased local impedance
and a reduction of radiofrequency current propagation in tissue,
thus yielding a smaller zone of coagulative necrosis. Newer
monopolar devices and modified techniques employing multiple-
array electrodes, saline infusion or cool-tip needles permit the
ablation of much larger zones than single non-array needle elec-
trodes; however, monopolar energy-based ablation is still chal-
lenged with prolonged ablation time, inconsistent ablation zone
and susceptibility to energy loss caused by convective heat loss
from adjacent high-velocity blood flows (‘heat sinks’).3,4
By contrast, bipolar RFA employs a dual parallel-electrode
array; the energy wave travels unidirectionally between and not
around electrodes. This ‘line-of-sight’ energy delivery streams
energy between two fixed points and concentrates energy delivery
to the area between the probes. Bipolar devices provide a stronger
current density and reduce dependency on thermal conduction,
which subsequently reduces dramatically the amount of time
required for ablation, and reduces or eliminates convective heat
loss from adjacent high-velocity blood flows.
In this study, we evaluate a novel laparoscopic bipolar RFA
device and describe a technique for treatment of hepatic tumours.
The purpose of this study was to evaluate the feasibility, ablation
time and safety profile of this novel technology.
Materials and methods
Using the prospectively maintained surgical oncology hepatic-
pancreatic-biliary database, we identified 17 consecutive patients
with 26 liver tumours who received bipolar ablations between
September 2007 and July 2008. Medical records were retrospec-
tively reviewed. The study was approved by our institutional
review board.
The laparoscopic InCircleTM (RFA Medical, Inc., Fremont, CA,
USA) is a bipolar RFA device approved by the US Food and Drug
Administration (Fig. 1). Two electrodes are placed at the periph-
ery of the desired ablation area with the guidance of intraopera-
tive ultrasound. No saline infusion is required; the energy is
efficiently delivered into the target area. No grounding pads are
required, eliminating the potential risk of cutaneous burns. The
InCircleTM device is compatible with a variety of standard RF
generators already in use for monopolar RFA via a connector
adapter. For reference purposes, the 3.5-cm ablation array is com-
posed of four total loops on each electrode (¥2) with a deployed
diameter of 1.7 cm on each side of each electrode such that a
composite deployment diameter of 3.4 cm is achieved; the 5-cm
ablation device uses the above configuration, but a composite
diameter of 4.5 cm is achieved [product literature as supplied by
the manufacturer RFA IFU-05388 RevA 2007]. (A 7-cm device is
also available, but was not used in this series.) The device is avail-
able in a both a 15-cm length for open use and a 25-cm length for
laparoscopic use (Fig. 1). In keeping with standard practice for
RFA devices, a 2-cm maximal diameter tumour would be ablated
with a 3.5-cm device, whereas a 4-cm maximal diameter tumour
would require a 5-cm device. The maximal distance between the
two electrodes for the 3.5-cm and 5-cm devices are 4.5 cm and
6.5 cm, respectively; these distance limits are necessary to main-
tain bipolar function rather than a transitional stage because as
distance is increased beyond the recommendations, the transi-
tional stage yields independent monopolar electrodes.
Generator timer and power settings employed for this series
were as per the manufacturer’s instructions [RFA IFU-05388
RevA 2007]; the 3.5-cm device used an initial power setting of
60–80 watts ¥ 3:00 min, and the 5-cm device used an initial power
setting of 100–135 watts ¥ 5:00 min. Confirmation of complete
ablation for the purposes of this study was performed by
re-starting power mode with demonstration of maximal imped-
ance reached.
In general, bipolar energy is considered safe and efficient. This
observation is based on the elimination of the need for grounding
pads, which precludes the occurrence of skin burns. Additionally,
the ability to focus energy into a well-defined area results in a safer
application of energy. Because this is a dual-electrode system,
there is an incremental risk inherent in placing two electrodes over
the risk associated with single-electrode systems and appropriate
care should be taken.
In the present series, all ablations were performed laparoscopi-
cally using the following technique: patients maintained a supine
Figure 1 Bipolar radiofrequency ablation device with two parallel
electrodes deployed facing one another
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position and general endotracheal anaesthesia was administered.
No hepatic inflow occlusion was performed for ablation. One
5-mm port and one 12-mm port were used in addition to the
camera port. Diagnostic laparoscopy was performed first to rule
out extrahepatic metastases. The falciform ligament was taken
down up to the decussation into the right and left coronary liga-
ments. Then the right triangular ligament was taken down to free
up the right lobe of the liver. At this point, a laparoscopic ultra-
sound probe (Aloka 5500; Aloka America, Wallingford, CT, USA)
was introduced through the 12-mm port to confirm the exact
location and dimensions of the tumour. As with other multi-
needle systems, placing two electrodes requires additional consid-
eration as to their placement paths; thus some additional planning
is necessary compared with a single-needle procedure. The bipolar
system also requires the electrodes to be placed to the side of the
tumour to be ablated and not at the centre. To help facilitate this
manoeuvre, a variety of techniques can be used for placement
depending on the operator’s preferences. Our preferred method is
to use intraoperative ultrasound guidance to place two 18-gauge
spinal needles (trajectory planning needles) through separate skin
incisions on either side of the tumour, about 1 cm from the
tumour border, so that the tumour is located between the needles.
These needles are used to aim the percutaneous electrode trajec-
tory into the liver. In our institution a stock Boston Scientific RTC
3000 generator was used for the energy source, with a bipolar
converter. The bipolar electrodes are percutaneously introduced
along the trajectory planning needles and deployed in the liver
parenchyma. Ablation is commenced as per the manufacturer’s
instructions at 60 watts, increasing incrementally to 80 watts after
2 min. The generator is powered ‘on’ until tissue impedance peaks
at 400, denoting complete ablation. Complete ablation is con-
firmed by a confirmatory ablation performed by restarting the
initial ablation protocol until peak impedance is achieved, which
usually takes <1 min.
Next, the electrodes are undeployed and withdrawn, without
track ablation. Ablation time is recorded as the total time for
ablation plus confirmatory burn for each tumour in seconds.
Radiological follow-up protocol
To our knowledge, no evidence-based consensus for the optimal
radiographic imaging interval for post-ablation follow-up and
surveillance has been defined. A generally accepted paradigm,
which we also utilize, is to obtain a triple-phase, 5-mm cut com-
puted tomography (CT) scan for this purpose. If the patient is to
receive adjuvant chemotherapy (i.e. in colorectal metastases), a
baseline CT as defined above is obtained at 1 month post-RFA and
prior to the initiation of systemic chemotherapy by medical
oncology protocol and subsequently every 3 months for the next 2
years. Conversely, for hepatocellular carcinoma (HCC), non-
colorectal adenocarcinoma and solid benign lesions, the initial CT
occurs at 3 months post-ablation. Other than in known benign
disease, CT is repeated at this interval (q3 months) for 2 years.
Results
A total of 26 lesions in 17 consecutive patients were ablated using
bipolar RFA over a period of 9 months. The patients included
eight women and nine men, with a median age of 65 years (range
27–79 years). In all, 18 lesions in 12 patients represented meta-
static lesions from colorectal cancer; six of these patients were
synchronous in presentation (colon primary with liver metastasis)
and chemotherapy-naive. Three lesions in two patients repre-
sented HCC; both patients were well compensated cirrhotics, aged
>70 years and grade B per child–Pugh Classification. Four lesions
in two patients were locally advanced symptomatic gallbladder
cancer invading the liver bed or intrahepatic liver metastases from
gallbladder cancer. One lesion was benign hepatic adenoma. Mean
tumour size was 3.07  1.42 cm. Mean ablation time was 358 
120 sec, or 5 min 58 sec (Table 1).
In this series, the role of bipolar RFA in six of the 12 colorectal
cancer patients was a bridge to resection because the patients
involved were deemed high risk for combined hepatic and
primary colorectal resection for synchronous disease presenta-
tion. The high-risk designation was based on the patients being
designated ASA grade 3 and aged >75 years. Five of the six under-
went definitive formal hepatic resection after four cycles of sys-
temic chemotherapy (FOLFOX), with no evidence of active
disease identified on pathology. The sixth patient declined hepatic
resection and has not demonstrated active disease by PET
(positron emission tomography) imaging.
No complications, defined as hepatic abscess, biliary injury or
leak, haemorrhage or cutaneous burn were observed in the 30-
day or >30-day post-RFA periods; all patients in this series were
followed for 30 days, with the longest follow-up being 12
months.
Discussion
The various technologies available for thermal ablation of hepatic
tumours vary widely by type of energy delivered and energy deliv-
ery efficiency. The effectiveness of the most commonly utilized
modality, monopolar RFA, is challenged with inconsistent abla-
tion zones dependent on heat sink effects and prolonged ablation
times.4 Modified monopolar devices employing saline infusion or
cool-tip techniques demonstrate an increased ablation zone but
add complexity to the procedure without reducing ablation time.
By contrast, bipolar RFA has the advantage of providing very high
current density (and therefore very high heating) between elec-
trodes and does not require external grounding.
In the literature, the reported duration of monopolar ablation
varies widely; however, in all citations, the reported ablation time
is much longer than that cited in the present report using bipolar
RFA. Poon et al., for example, describe a series of 100 cases using
monopolar RFA with an average ablation time of 21 min.5 Addi-
tionally, two other smaller studies reported similar findings.6,7 It is
also important to note that in these monopolar RFA series, the
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reported tumour sizes ablated were smaller than in the present
bipolar series (Table 2). In the present series, complete bipolar
ablation was achieved in a mean of 5 min 58 sec for 26 consecutive
lesions, which is just a fraction of the duration reported for
monopolar RFA ablation in the studies cited earlier.
A potential limitation of the bipolar RFA technique compared
with monopolar systems concerns its requirement for an addi-
tional electrode. This additional intraoperative manoeuvre does
not represent a major challenge to a surgeon who is confident
using guidance by ultrasound. It is important to comment on the
potential for electrodes not to be perfectly parallel to one another
and to note that this impacts on the shape of the ablation zone.
With bipolar devices, the energy travels in a line-of-sight manner.
Thus, the resulting ablation will be shaped according to how the
electrodes are placed. For example, if the two electrodes are placed
so that they are parallel and are aligned to one another at the
nominal separation distance, the resulting ablation will be either
square with rounded edges or spherical, depending on which size
of device is used. If the devices are placed parallel but are offset
from one another, a 3-dimensional parallelogram will be formed.
Table 1 Data for 26 lesions in 17 consecutive patients treated using bipolar radiofrequency ablation
Lesion Disease Size, cm Ablation time*, sec
1 CRLM N/A 280
2 CRLM 5.0 725
3 CRLM 3.0 478
4 CRLM 2.0 350
5 CRLM 3.5 284
6 CRLM 2.3 310
7 CRLM 3.0 428
8 CRLM 1.5 290
9 CRLM 1.5 258
10 CRLM 1.5 601
11 CRLM 1.2 277
12 Hepatic adenoma 1.0 332
13 Gallbladder Ca N/A (gallbladder bed ablation) 270
14 HCC 2.6 260
15 Gallbladder LM 2.0 270
16 Gallbladder LM 2.5 270
17 Gallbladder LM 3.6 300
18 HCC 6.0 450
19 HCC 5.0 420
20 CRLM N/A (resection bed ablation for margin) 295
21 CRLM 3.0 368
22 CRLM 5.0 468
23 CRLM 4.5 265
24 CRLM 3.0 285
25 CRLM 3.0 266
26 CRLM 5.0 513
Mean 3.07  1.42 358  120
*Ablation time = ablation + confirmation burn
CRLM, colorectal liver metastasis; HCC, hepatocellular carcinoma; LM, liver metastasis; N/A, not available
Table 2 Data from series investigating monopolar radiofrequency ablation compared with data from the current study
Study Lesions, n Mean size, cm Mean ablation time, min
Zytoon et al. (2007)7 48 2.02 20.6
Nakamuta et al. (2006)6 13 2.20 22.1
Poon et al. (2004)5 100 2.80 21.0
Current study 26 3.07 5.97
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Likewise, if the devices are placed at an angle to one another, a
trapezoid or quadrilateral ablation will be created. Understanding
the characteristics of the device enable the operator to tailor the
desired ablation shape according to the physical location and
other conditions of the individual tumour. The key aspect in all
cases is to ensure that the electrodes are placed so as to define the
outer perimeter of the desired ablation. This bipolar approach,
requiring two needles, results in a significant reduction in ablation
time compared with times published for monopolar ablation.
Experimental data to further underscore the characteristics of
bipolar RFA energy have been reported from several ex vivo or
animal studies. These studies show that bipolar RFA creates larger
lesions and is less dependent on local inhomogenities of liver
tissue compared with monopolar RF ablation.8–10 Additionally in
these studies, the measured ablation area was consistent, the abla-
tion was always located between two electrodes where the energy
was delivered and, importantly, convective heat loss from adjacent
high-velocity blood flows was negligible.
Microwave ablation is another new technique also reported to
be quick, a characteristic which is consistent with minimal con-
vective heat loss from adjacent high-velocity blood flows com-
pared with monopolar RFA. At least two different systems have
become available during the past year (a 245-MHz system and a
915-MHz system). Further potential advantages of MWA include
real-time ultrasound monitoring during ablation, which is not
possible with RFA. Microwave ablation is limited in that it
requires an array of three needles, which need to be carefully
spaced percutaneously to prevent skin burns, and grounding
pads. Early preclinical experience indicates ablation times of
10–12 min.11 The additional capital outlay required for energy
generators, estimated to be in the range of $90 000, is also
significant.
Furthermore, MWA has been experimentally demonstrated to
have potentially detrimental effects to the liver (245-MHz
system). In an animal study, Garrean et al.12 showed that MWA
could easily cause necrotic coagulation of blood vessels and exten-
sion of venous thrombosis as a result of ‘thermal tracking’, and was
also observed to fracture hepatic parenchyma. These safety con-
cerns will need to be carefully addressed before widespread clini-
cal application of MWA can be achieved.
By contrast, bipolar RFA offers reduced ablation times com-
pared with the published monopolar RFA experience, demon-
strates consistent ablation zones, and involves minimal convective
heat loss from adjacent high-velocity blood flows. Importantly,
any centre that already performs monopolar ablation procedures
does not require additional capital equipment beyond an adapter
for bipolar RFA.
In conclusion, we present the first series of laparoscopic bipolar
RFA of liver tumours. The results demonstrate that bipolar RFA is
a quick and safe technique which adds a new tool to our arma-
mentarium for the treatment of hepatic tumours. Establishing the
longterm oncological outcome will require longer follow-up and
the exact role of this technique in the current multimodality man-
agement remains to be defined.
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